NETRIS PHARMA
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the pharmaceutical industry. The dependence receptors are trans-membrane proteins that receive signals and transmit them inside cells and this helps in controlling tumor development. The company provides vitro and in vivo research, preclinical practices for manufacturing drugs for the treatment of breast cancer, lung cancer, glioblastoma and neuroblastoma cancer.
NETRIS PHARMA
Industry:
Biotechnology Health Care Life Science Pharmaceutical
Founded:
2008-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.netrispharma.com
Total Employee:
1+
Status:
Active
Contact:
+33 4 78 78 29 53
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Chiracon
Chiracon is the global point of contact for the production of high-quality intermediate and end products for the pharmaceutical industry.
Current Advisors List
Current Employees Featured
Official Site Inspections
http://www.netrispharma.com Semrush global rank: 5.86 M Semrush visits lastest month: 1.41 K
- Host name: ec2-13-39-77-176.eu-west-3.compute.amazonaws.com
- IP address: 13.39.77.176
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "NETRIS Pharma"
Home - NETRIS PHARMA
NETRIS Pharma is a unique model of a clinical-stage immuno oncology company integrated within a comprehensive cancer center.See details»
About us - NETRIS PHARMA
Sep 4, 2024 · NETRIS Pharma is dedicated to provide novel therapeutic solutions to patients suffering from cancer. We leverage our in-depth understanding of tumor evasion mechanisms to develop innovative treatments able to …See details»
NETRIS Pharma, Orano and Centre Léon Bérard Announce …
Sep 20, 2022 · LYON, France — NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with …See details»
NETRIS Pharma - LinkedIn
NETRIS Pharma is a clinical-stage biopharmaceutical company developing innovative therapeutic molecules targeting NETRIN-1, a protein aberrantly expressed in cancer cells that triggers EMT, one...See details»
NETRIS Pharma, Orano and Centre Léon Bérard Announce …
Sep 20, 2022 · LYON, France-- ( BUSINESS WIRE )--NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific …See details»
NETRIS PHARMA SAS - European Commission - European …
Netris Pharma is a clinical-stage immuno oncology company. Its lead asset induces cancer cell death and reduces tumor plasticity, thereby alleviating resistance to chemotherapies, targeted …See details»
NETRIS Pharma led consortium awarded €1.2 million …
Jan 20, 2023 · Lyon, Copenhagen and Stockholm — NETRIS Pharma, a clinical-stage private biopharmaceutical company developing a new class of drugs based on dependence receptor biology, today announced that a...See details»
Suggested articles - NETRIS PHARMA
Dec 19, 2023 · NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer resistance, today announced that it has expanded its …See details»
NETRIS Pharma - Crunchbase Company Profile & Funding
View contacts for NETRIS Pharma to access new leads and connect with decision-makers. NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence …See details»
NETRIS Pharma - Products, Competitors, Financials, Employees ...
NETRIS Pharma focuses on oncology. It develops therapeutic products that target a mechanism of cancer resistance, offering new solutions to patients that alleviate resistance to …See details»
NETRIS Pharma - Craft
See insights on NETRIS Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
NETRIS Pharma, Orano and Centre Léon Bérard Announce
Sep 20, 2022 · LYON, France—NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with …See details»
NETRIS Pharma extends Series A to €24.4 million and reinforces its ...
Dec 19, 2023 · Gabriela has held many leadership positions within pharmaceutical companies, and more recently was Senior Vice President and Head of Regulatory Affairs Oncology at …See details»
Pipeline - NETRIS PHARMA
NETRIS Pharma's clinical development plan encompasses five recruiting clinical trials aimed at confirming the ability of its lead asset, NP137, to reduce tumors growth and aggressiveness as …See details»
Netris Pharma SA Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Netris Pharma SA of Genève, GENÈVE. Get the latest business insights from Dun & Bradstreet.See details»
Netris Pharma Company Profile 2024: Valuation, Funding
Operator of a biopharmaceutical company intended to drive superior clinical benefits for patients in the treatment of cancer.See details»
Concept & Strategy - NETRIS PHARMA
NETRIS Pharma lead asset is designed to block the interaction between netrin-1 and its main receptors unc5B to restore cell death, inhibit phenotypic plasticity and prevent metastases …See details»
NETRIS Pharma Announces Clinical Trial Collaboration
May 5, 2020 · Under the terms of the agreement, NETRIS will sponsor a large phase 1b/2 study, which will be conducted in collaboration with the Centre Léon Bérard and with support of the …See details»
NP137-Lead asset - NETRIS PHARMA
NP137 was engineered to specifically and efficiently bind to netrin-1 and to inhibit the interaction between ligand and receptor. Netrin-1 functions both as a survival factor and an inducer of …See details»
NETRIS Pharma extends Series A to €24.4 million and reinforces its ...
Dec 19, 2023 · During her tenure, Gabriela was responsible for leading a world class oncology regulatory affairs organization of approximately 120 associates. Jean-Pierre Bizzari, Chairman …See details»